Mark McPartland
Senior Vice President, Investor Relations, Vistagen Therapeutics
Replay available
Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Q2 2025 earnings conference call, held 2024-11-07. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Sean Singh
Chief Executive Officer, Vistagen Therapeutics
Josh Prince
Chief Operating Officer, Vistagen Therapeutics
Cindy Anderson
Chief Financial Officer, Vistagen Therapeutics
Andrew Tai
Analyst, Jefferies
Miles Minter
Analyst, William Blair
Madison Elzadi
Analyst, B. Riley Securities
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Vistagen Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.817 Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal 00:00:04.817 -- 00:00:06.439 Year 2025 00:00:06.439 -- 00:00:11.003 Second Quarter Corporate Update Conference Call. 00:00:11.726 -- 00:00:14.610 At this time, all lines are in listen-only mode. 00:00:14.610 -- 00:00:19.016 Following the presentation, we will conduct a question and answer session. 00:00:19.016 -- 00:00:23.862 If at any time during this call you require immediate assistance, please press star zero 00:00:23.862 -- 00:00:29.640 for the operator. This call is being recorded on Thursday, November 7, 2024. 00:00:29.640 -- 00:00:31.043 I 00:00:31.043 -- 00:00:33.566 would now like to turn the call over to Mr. 00:00:33.566 -- 00:00:39.115 Mark McPartland, Senior Vice President, Investor Relations at Vistagen. 00:00:39.115 -- 00:00:41.716 Please go ahead. 00:00:42.259 -- 00:00:46.967 Thank you, Operator. Good afternoon, everyone, and welcome to Vistagen's fiscal year 00:00:46.967 -- 00:00:48.529 2025 00:00:48.529 -- 00:00:51.938 second quarter corporate update conference call and webcast. 00:00:51.938 -- 00:00:56.963 Earlier this afternoon, we filed our quarterly report with the Securities Exchange Commission 00:00:56.963 -- 00:01:03.048 on the SEC Form 10-Q for our second quarter that ended September 30, 2024. 00:01:03.350 -- 00:01:07.335 And we also issued a press release providing an overview of our progress across our lead 00:01:07.335 -- 00:01:12.400 neuroscience programs. We encourage you to review the release and our 10-Q, 00:01:12.400 -- 00:01:16.563 which can be found in the investor section of our website. 00:01:17.453 -- 00:01:21.379 We will make forward-looking statements regarding our business during today's call based 00:01:2...